Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: A cross sectional study

Eur J Obstet Gynecol Reprod Biol. 2018 Mar:222:119-125. doi: 10.1016/j.ejogrb.2018.01.025. Epub 2018 Feb 3.

Abstract

Study objectives: To investigate the effect of N312S polymorphism in the LHCGR gene as a predictive pharmacogenetic marker on clinical and embryological parameters and determining the need of r-hLH supplementation combine with r-hFSH in patients undergoing ART treatment.

Study design: In a cross-sectional study, a retrospective analysis of women (n = 553), who underwent controlled ovarian stimulation treatment protocol was conducted during the years 2012-2014. R-hFSH (Gonal-F, Merck Serono) was administered to all patients undergoing ART cycle after initiating long luteal gonadotrophin-releasing hormone (GnRH) agonist down-regulation. R-hLH was supplemented based on P.C. Wong criteria. N312S genotype was determined using sequencing methodology. The mean r-hFSH, r-hLH doses, total number of oocytes, cleavage rates of embryos and clinical pregnancy were recorded. The association between the r-hLH supplementation and LHCGR N312S polymorphism and clinical pregnancy rates was determined using regression analysis by SPSS.

Results: 19.7% of women were homozygous for A allele encoding asparagine (N/N), 45.7% were heterozygous (N/S) and 34.6% were homozygous (S/S) for G allele encoding serine. Women heterozygous (N/S) or homozygous (S/S) for serine showed a higher requirement for r-hLH (OR, 95% p-trend = <0.0001) compared to those homozygous for asparagine (N/N). Homozygous G allele was also associated with higher daily and total r-hLH dose per treatment cycle p-trend = <0.0001. Though, the total no of oocytes (14.87 ± 4.95 vs 12.98 ± 5.39 and 13.58 ± 5.45), Gr-I quality embryos (2.61 ± 1.81 vs 2.18 ± 1.96 and 1.98 ± 2.05) were significantly higher in women homozygous for A allele compared to women with heterozygous and homozygous for G allele, clinical pregnancy rates were significantly more in women with for G allele after excluding patients with PCOS and endometriosis conditions (P < 0.04).

Conclusion: The present findings reveal that women heterozygous and homozygous for G allele required higher doses of r-hLH supplementation and these women were shown to have higher clinical pregnancy rates.

Keywords: In vitro fertilization; LH supplementation; LHCGR polymorphism; N312S; rs2293275.

MeSH terms

  • Adult
  • Amino Acid Substitution
  • Cohort Studies
  • Cross-Sectional Studies
  • Dose-Response Relationship, Drug
  • Drug Resistance / genetics*
  • Female
  • Fertility Agents, Female / administration & dosage
  • Fertility Agents, Female / metabolism
  • Fertility Agents, Female / pharmacology
  • Fertilization in Vitro
  • Follicle Stimulating Hormone / genetics
  • Follicle Stimulating Hormone / metabolism
  • Follicle Stimulating Hormone / pharmacology
  • Genetic Association Studies
  • Growth Hormone-Releasing Hormone / agonists*
  • Growth Hormone-Releasing Hormone / metabolism
  • Humans
  • India
  • Infertility, Female / genetics
  • Infertility, Female / metabolism
  • Infertility, Female / therapy*
  • Luteinizing Hormone / administration & dosage
  • Luteinizing Hormone / genetics
  • Luteinizing Hormone / metabolism
  • Luteinizing Hormone / pharmacology*
  • Ovulation Induction*
  • Pharmacogenetics / methods
  • Polymorphism, Single Nucleotide*
  • Receptors, LHRH / genetics*
  • Receptors, LHRH / metabolism
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / pharmacology
  • Retrospective Studies

Substances

  • Fertility Agents, Female
  • GNRHR protein, human
  • Receptors, LHRH
  • Recombinant Proteins
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Growth Hormone-Releasing Hormone